Phosphodiesterase-4 Inhibition in Psoriasis
Milica Milakovic,1 Melinda J Gooderham2– 4 1Faculty of Medicine, University of Toronto, Toronto, ON, Canada; 2Skin Centre for Dermatology, Peterborough, ON, K9J 5K2, Canada; 3Probity Medical Research, Waterloo, ON, N2J 1C4, Canada; 4Department of Medicine, Queen’s University, Kin...
Guardado en:
Autores principales: | Milakovic M, Gooderham MJ |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ab2d804e082e400694d7b6fb14a36246 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Management of scalp psoriasis: current perspectives
por: Blakely K, et al.
Publicado: (2016) -
Psoriasis In Patients With Active Lung Cancer: Is Apremilast a Safe Option?
por: Zoe Apalla, et al.
Publicado: (2019) -
Tacrolimus for the management of psoriasis: clinical utility and place in therapy
por: Malecic N, et al.
Publicado: (2016) -
Perspective trends of topical therapy of patients with psoriasis
por: Alexander S. Zhukov, et al.
Publicado: (2021) -
Small Molecules, Big Promises: Improvement of Psoriasis Severity and Glucidic Markers with Apremilast: A Case Report
por: Lanna C, et al.
Publicado: (2019)